Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levulinic Acid SCHEMBL9767579 | 0.94 | — | — | |
| Levulinic Acid SCHEMBL21815796 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL10791493 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL2074646 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL439418 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL25222492 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL21815632 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL21815652 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL21815731 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL11315082 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2695871-B1 | High performance material for a pyrotechnic decoy flare with a fluorinated carbon compound | DIEHL DEFENCE GMBH & CO KG (DE) | 2021-03-03 | — | — | EP | claimed |
| US-9139487-B2 | Active composition for a decoy which radiates spectrally on combustion of the active composition, containing an additive | DIEHL BGT DEFENCE GMBH & CO. KG (DE) | 2015-09-22 | — | — | US | claimed |
| US-9133071-B2 | Active composition for a decoy which radiates spectrally on combustion of the active composition | DIEHL BGT DEFENCE GMBH & CO. KG (DE) | 2015-09-15 | — | — | US | claimed |
| US-20150047760-A1 | ACTIVE COMPOSITION FOR A DECOY WHICH RADIATES SPECTRALLY ON COMBUSTION OF THE ACTIVE COMPOSITION, CONTAINING AN ADDITIVE | DIEHL BGT DEFENCE GMBH & CO. KG (DE) | 2015-02-19 | — | — | US | claimed |
| EP-2062874-B1 | Process and intermediates for the preparation of aliskiren | KRKA TOVARNA ZDRAVIL D D NOVO MESTO (SI) | 2014-12-17 | — | — | EP | claimed |
| US-20140060711-A1 | ACTIVE COMPOSITION FOR A DECOY WHICH RADIATES SPECTRALLY ON COMBUSTION OF THE ACTIVE COMPOSITION | DIEHL BGT DEFENCE GMBH & CO. KG (DE) | 2014-03-06 | — | — | US | claimed |
| EP-2062874-A1 | Process and intermediates for the preparation of aliskiren | KRKA, tovarna zdravil, d.d., Novo mesto (SI) | 2009-05-27 | — | — | EP | claimed |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
| EP-3856257-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | Ascendis Pharma A/S (DK) | 2021-08-04 | — | — | EP | disclosed |
| EP-3856255-A1 | TREATMENT OF INFECTIONS | Ascendis Pharma A/S (DK) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020064844-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020064847-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | ASCENDIS PHARMA A/S (DK) | 2020-04-02 | — | — | WO | disclosed |
| US-10239293-B2 | Composite part | LANXESS DEUTSCHLAND GMBH (DE) | 2019-03-26 | — | — | US | disclosed |
| US-5448419-A | Apparatus and method for anhysteretically recording from master drum to slave web | EASTMAN KODAK COMPANY (US) | 1995-09-05 | — | — | US | disclosed |
| US-5230818-A | Applying undercoating; durability | EASTMAN KODAK COMPANY (US) | 1993-07-27 | — | — | US | disclosed |
| EP-0550351-A1 | Coating compositions for master media for anhysteretic recording | EASTMAN KODAK COMPANY (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0256162-A1 | Polyol/Polyepoxide/Polyisocyanate Adhesive composition and its use | Ashland Oil, Inc. (US) | 1988-02-24 | — | — | EP | disclosed |
| US-4726868-A | SOLVENT-FREE | ASHLAND OIL, INC. (US) | 1988-02-23 | — | — | US | disclosed |
| US-4613660-A | TIN AND IRON CATALYST | ASHLAND OIL, INC. (US) | 1986-09-23 | — | — | US | disclosed |
| US-3970713-A | Process for the production of allyl alcohol | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330798-A1 | TREATMENT OF INFECTIONS | H1-10, PM20D2, ELANE | ALDH1A1 1667/4885FFAR3 4182/4885HDAC3 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.